All
Emactuzumab Gets Fast Track Designation in Tenosynovial Giant Cell Tumors
Emactuzumab has received fast track designation from the U.S. FDA for patients with tenosynovial giant cell tumors and who would not benefit from surgery.
Raising Awareness on Multidisciplinary Approaches in GI Cancers
Patients with gastrointestinal cancer may benefit from multidisciplinary care and open communication with their care team, as per an expert.
FDA sBLA Submitted for Anktiva Plus BCG in Papillary Bladder Cancer
A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.
TLX101 Demonstrated Efficacy in Recurrent High-Grade Glioma
TLX101 therapy was efficacious in recurrent high-grade glioma, a type of brain cancer, according to preliminary results from the phase 2 IPAX-Linz study.
15% of U.S. Cancer Patients Are Active Smokers at Time of Diagnosis
The addition of smoking status to the National Cancer Database might inform more effective treatment for smokers with cancer.
Sometimes, Distractions Help During Breast Cancer
After a mammogram and breast cancer scare, a Broadway show provided a welcome distraction and joy, reminding me of life's beauty.
Bria-IMT Combo Outperforms Other Metastatic Breast Cancer Treatments
Bria-IMT plus check point inhibitors had a median overall survival which outperformed that of antibody-drug conjugates in HR+ metastatic breast cancer.
Bexmarilimab Plus Vidaza Elicit Responses in Myelodysplastic Syndromes
Treatment with bexmarilimab and Vidaza elicited high overall response rates in both frontline and relapsed/refractory higher-risk myelodysplastic syndrome.
Understanding Esophageal Cancer: Early Signs, Risks and Key Insights
Dr. Nataliya Uboha sat down to discuss the early warning signs of esophageal cancer, as well as important key takeaways for those with the disease.
Erleada Reduces Risk of Death in Metastatic Prostate Cancer Subset
Erleada reduced the risk of death by more than 20% compared with other treatments in metastatic castration-sensitive prostate cancer.
Subcutaneous Opdivo Similarly Effective, Safe as IV for Advanced ccRCC
Subcutaneous Opdivo showed comparable effectiveness, safety and tolerability to IV Opdivo in advanced clear cell renal cell carcinoma.
Spring Looks Different This Year
What is lovely never dies, but passes into other loveliness, Stardust or seafoam, flower or winged air. ― Thomas Bailey Aldrich
First Patient Treated in Trial of PHST001 for Advanced Solid Tumors
Pheast Therapeutics has treated the first patient in a phase 1 trial of PHST001, a novel macrophage checkpoint inhibitor for advanced solid tumors.
Clinical Trial of NEO100 Recruiting Patients With Malignant Gliomas
A phase 2a clinical trial of NEO100-01 is continuing to recruit patients with malignant gliomas, with full enrollment expected in September.
Nubeqa Combo Improves Outcomes in Metastatic Prostate Cancer
Nubeqa plus hormone therapy improved outcomes in metastatic prostate cancer, reducing disease progression and showing a favorable safety profile.
Expanding Definition of Cancer Survivorship Highlights Need for New Standards
Tara Sweeney, BSN, RN, OCN, CHPN discussed best care for the health and well-being of a person across all stages of their cancer survivorship.
Radiation Therapy Advances Improve Quality of Life for GI Cancer
Advancements in radiation therapy, including proton therapy and stereotactic radiation, reduce side effects and improve quality of life for GI cancer.
FDA Approves Cabometyx, Another Treatment for Neuroendocrine Tumors
The FDA has approved Cabometyx for some patients 12 years old and older with previously treated neuroendocrine tumors.
Springtime Health After My Testicular Cancer Diagnosis
Experiencing spring's renewal after a cancer diagnosis, I focus on health through checkups, diet and exercise, embracing change and well-being.
AU-007 Combo Dosing Begins in Melanoma Phase 2 Trial With Opdivo
AU-007, combined with Opdivo and low-dose aldesleukin, has entered a phase 2 melanoma trial, with early data showing activity and manageable safety.
Trial of SVV-001, Opdivo and Yervoy in Neuroendocrine Tumors Launching
A phase 1 clinical trial is open for enrollment to patients with high-grade neuroendocrine tumors.
Early Detection Critical for Testicular Cancer in Young Men
April serves as Testicular Cancer Awareness Month, which is the most common type of cancer in men aged between 15 and 44 years old.
Ziftomenib Submits New Drug Application to FDA for R/R NPM1-Mutant AML
The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.
Phase 3 Trial Leads to FDA Approval of Cabometyx in Neuroendocrine Tumors
Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine tumors.
NeroSAFE May Increase Erectile Function After Prostate Cancer Surgery
Use of NeuroSAFE during prostatectomy nearly doubled the number of patients who had no or mild erectile dysfunction approximately a year later.
First Patient Dosed With KSQ-004EX In Solid Tumor Clinical Trial
KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic and cervical cancer.
Imdelltra May Improve Survival in Small Cell Lung Cancer
Imdelltra is associated with improvement in overall survival compared to local standard-of-care chemotherapy among patients with small cell lung cancer.
A Kidney Cancer Advocate Shares Advice for Newly Diagnosed Patients
Some cancer statistics may reflect 'backwards-looking data', making it important to stay up to date on reliable information and happenings in the space.
Knowing the Signs to Detect and Treat Testicular Cancer Early
Testicular cancer is rare but highly curable, especially with early detection; treatment varies by stage, and follow-up care supports long-term health.
Spring Forward: How I Stay Grounded and Hopeful with Lynch Syndrome
Living with Lynch isn't easy, but it's not all doom and gloom. It's a call to live deliberately.
